Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach.

Xiao Z, Sperl B, Gärtner S, Nedelko T, Stacher-Priehse E, Ullrich A, Knyazev PG.

Oncotarget. 2019 Apr 2;10(26):2546-2560. doi: 10.18632/oncotarget.26817. eCollection 2019 Apr 2.

2.

Charge Transfer Complexes Formed by Heterocyclic Thioamides and Tetracyanoethylene: Experimental and Theoretical Study.

Kolesnikova TS, Chernov'yants MS, Kletskii ME, Burov ON, Bondarenko GI, Knyazev PA.

J Phys Chem A. 2017 Sep 21;121(37):7000-7008. doi: 10.1021/acs.jpca.7b00564. Epub 2017 Sep 12.

PMID:
28849931
3.

Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients.

Xiao Z, Gaertner S, Morresi-Hauf A, Genzel R, Duell T, Ullrich A, Knyazev PG.

Neoplasia. 2017 May;19(5):385-395. doi: 10.1016/j.neo.2017.02.011. Epub 2017 Apr 7.

4.

Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases.

Sommer AK, Hermawan A, Mickler FM, Ljepoja B, Knyazev P, Bräuchle C, Ullrich A, Wagner E, Roidl A.

Oncotarget. 2016 Aug 2;7(31):50461-50476. doi: 10.18632/oncotarget.10459.

5.

Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines.

Gusenbauer S, Zanucco E, Knyazev P, Ullrich A.

Mol Cancer. 2015 Mar 4;14:54. doi: 10.1186/s12943-015-0319-z.

6.

Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells.

Kopp F, Hermawan A, Oak PS, Ulaganathan VK, Herrmann A, Elnikhely N, Thakur C, Xiao Z, Knyazev P, Ataseven B, Savai R, Wagner E, Roidl A.

Transl Oncol. 2014 Dec;7(6):702-11. doi: 10.1016/j.tranon.2014.09.002.

8.

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs.

Ataseven B, Gunesch A, Eiermann W, Kates RE, Högel B, Knyazev P, Ullrich A, Harbeck N.

Onco Targets Ther. 2014 Oct 6;7:1723-31. doi: 10.2147/OTT.S62676. eCollection 2014.

9.

PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement.

Gärtner S, Gunesch A, Knyazeva T, Wolf P, Högel B, Eiermann W, Ullrich A, Knyazev P, Ataseven B.

PLoS One. 2014 Jan 7;9(1):e84472. doi: 10.1371/journal.pone.0084472. eCollection 2014.

10.

PTK7 expression in triple-negative breast cancer.

Ataseven B, Angerer R, Kates R, Gunesch A, Knyazev P, Högel B, Becker C, Eiermann W, Harbeck N.

Anticancer Res. 2013 Sep;33(9):3759-63.

PMID:
24023307
11.

Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator.

Vlaicu P, Mertins P, Mayr T, Widschwendter P, Ataseven B, Högel B, Eiermann W, Knyazev P, Ullrich A.

BMC Cancer. 2013 Apr 18;13:197. doi: 10.1186/1471-2407-13-197.

12.

Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells.

Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, Wagner E, Knyazev P, Roidl A.

Int J Cancer. 2012 Dec 15;131(12):2808-19. doi: 10.1002/ijc.27595. Epub 2012 May 21.

13.

Synthesis, molecular and electronic structures of six-coordinate transition metal (Mn, Fe, Co, Ni, Cu, and Zn) complexes with redox-active 9-hydroxyphenoxazin-1-one ligands.

Ivakhnenko EP, Starikov AG, Minkin VI, Lyssenko KA, Antipin MY, Simakov VI, Korobov MS, Borodkin GS, Knyazev PA.

Inorg Chem. 2011 Aug 1;50(15):7022-32. doi: 10.1021/ic2004062. Epub 2011 Jun 30.

PMID:
21718042
14.

Protein tyrosine phosphatases expression during development of mouse superior colliculus.

Reinhard J, Horvat-Bröcker A, Illes S, Zaremba A, Knyazev P, Ullrich A, Faissner A.

Exp Brain Res. 2009 Dec;199(3-4):279-97. doi: 10.1007/s00221-009-1963-6. Epub 2009 Sep 1.

15.

Overexpression of Csk-binding protein contributes to renal cell carcinogenesis.

Feng X, Lu X, Man X, Zhou W, Jiang LQ, Knyazev P, Lei L, Huang Q, Ullrich A, Zhang Z, Chen Z.

Oncogene. 2009 Sep 17;28(37):3320-31. doi: 10.1038/onc.2009.185. Epub 2009 Jul 6.

PMID:
19581936
16.

Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation.

Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A.

Clin Cancer Res. 2009 Mar 15;15(6):2058-66. doi: 10.1158/1078-0432.CCR-08-0890. Epub 2009 Feb 24.

17.

UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines.

Singh B, Schneider M, Knyazev P, Ullrich A.

Int J Cancer. 2009 Feb 1;124(3):531-9. doi: 10.1002/ijc.23974.

18.

Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.

Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Körner H, Knyazev P, Diebold J, Hermeking H.

Cell Cycle. 2008 Aug 15;7(16):2591-600. Epub 2008 Aug 1.

PMID:
18719384
19.

HER3 is a determinant for poor prognosis in melanoma.

Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H, Ullrich A.

Clin Cancer Res. 2008 Aug 15;14(16):5188-97. doi: 10.1158/1078-0432.CCR-08-0186.

20.

AXL is a potential target for therapeutic intervention in breast cancer progression.

Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Kéri G, Ullrich A.

Cancer Res. 2008 Mar 15;68(6):1905-15. doi: 10.1158/0008-5472.CAN-07-2661.

21.

Receptor protein tyrosine phosphatases are expressed by cycling retinal progenitor cells and involved in neuronal development of mouse retina.

Horvat-Bröcker A, Reinhard J, Illes S, Paech T, Zoidl G, Harroch S, Distler C, Knyazev P, Ullrich A, Faissner A.

Neuroscience. 2008 Mar 27;152(3):618-45. doi: 10.1016/j.neuroscience.2008.01.016. Epub 2008 Jan 25.

PMID:
18308476
22.

Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme.

Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N, Knyazeva T, Barbieri V, Reindl M, Muigg A, Kostron H, Stockhammer G, Ullrich A.

Clin Cancer Res. 2008 Jan 1;14(1):130-8. doi: 10.1158/1078-0432.CCR-07-0862.

23.

Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines.

Ruhe JE, Streit S, Hart S, Wong CH, Specht K, Knyazev P, Knyazeva T, Tay LS, Loo HL, Foo P, Wong W, Pok S, Lim SJ, Ong H, Luo M, Ho HK, Peng K, Lee TC, Bezler M, Mann C, Gaertner S, Hoefler H, Iacobelli S, Peter S, Tay A, Brenner S, Venkatesh B, Ullrich A.

Cancer Res. 2007 Dec 1;67(23):11368-76.

24.

PTP-PEST phosphatase variations in human cancer.

Streit S, Ruhe JE, Knyazev P, Knyazeva T, Iacobelli S, Peter S, Hoefler H, Ullrich A.

Cancer Genet Cytogenet. 2006 Oct 1;170(1):48-53.

PMID:
16965954
25.

Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.

Ferby I, Reschke M, Kudlacek O, Knyazev P, Pantè G, Amann K, Sommergruber W, Kraut N, Ullrich A, Fässler R, Klein R.

Nat Med. 2006 May;12(5):568-73. Epub 2006 Apr 30. Erratum in: Nat Med. 2006 Jul;12(7):862.

PMID:
16648858
26.

Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation.

Jiang LQ, Feng X, Zhou W, Knyazev PG, Ullrich A, Chen Z.

Oncogene. 2006 Sep 7;25(40):5495-506. Epub 2006 Apr 24.

PMID:
16636672
27.

Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.

Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H, Kiessling F, Eichelsbacher U, Essig M, Read TA, Erber R, Ullrich A.

Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5799-804. Epub 2006 Apr 3.

28.

Structural basis for Gas6-Axl signalling.

Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Göhring W, Ullrich A, Timpl R, Hohenester E.

EMBO J. 2006 Jan 11;25(1):80-7. Epub 2005 Dec 15.

29.

FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression.

Stadler CR, Knyazev P, Bange J, Ullrich A.

Cell Signal. 2006 Jun;18(6):783-94. Epub 2005 Aug 18.

PMID:
16109476
30.

Identification of MMP-15 as an anti-apoptotic factor in cancer cells.

Abraham R, Schäfer J, Rothe M, Bange J, Knyazev P, Ullrich A.

J Biol Chem. 2005 Oct 7;280(40):34123-32. Epub 2005 Aug 9.

31.

Effect of tumor-associated mutant E-cadherin variants with defects in exons 8 or 9 on matrix metalloproteinase 3.

Fuchs M, Hermannstädter C, Specht K, Knyazev P, Ullrich A, Rosivatz E, Busch R, Hutzler P, Höfler H, Luber B.

J Cell Physiol. 2005 Mar;202(3):805-13.

PMID:
15389640
32.

Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains.

Sasaki T, Knyazev PG, Cheburkin Y, Göhring W, Tisi D, Ullrich A, Timpl R, Hohenester E.

J Biol Chem. 2002 Nov 15;277(46):44164-70. Epub 2002 Sep 5.

33.

A novel role for protein tyrosine phosphatase shp1 in controlling glial activation in the normal and injured nervous system.

Horvat A, Schwaiger F, Hager G, Brocker F, Streif R, Knyazev P, Ullrich A, Kreutzberg GW.

J Neurosci. 2001 Feb 1;21(3):865-74.

34.

Characteristics of EGFR family-mediated HRG signals in human ovarian cancer.

Campiglio M, Ali S, Knyazev PG, Ullrich A.

J Cell Biochem. 1999 Jun 15;73(4):522-32.

PMID:
10733345
35.

The receptor-like protein-tyrosine phosphatase DEP-1 is constitutively associated with a 64-kDa protein serine/threonine kinase.

Jallal B, Mossie K, Vasiloudis G, Knyazev P, Zachwieja J, Clairvoyant F, Schilling J, Ullrich A.

J Biol Chem. 1997 May 2;272(18):12158-63.

36.

Adapter function of protein-tyrosine phosphatase 1D in insulin receptor/insulin receptor substrate-1 interaction.

Kharitonenkov A, Schnekenburger J, Chen Z, Knyazev P, Ali S, Zwick E, White M, Ullrich A.

J Biol Chem. 1995 Dec 8;270(49):29189-93.

37.

Loss of heterozygosity at chromosome 17p is associated with HER-2 amplification and lack of nodal involvement in breast cancer.

Knyazev PG, Imyanitov EN, Chernitsa OI, Nikiforova IF.

Int J Cancer. 1993 Jan 2;53(1):11-6.

PMID:
8416194
38.

Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.

Imyanitov EN, Chernitsa OI, Serova OM, Nikoforova IF, Pluzhnikova GF, Knyazev PG.

Neoplasma. 1993;40(1):35-9.

PMID:
7688867
39.

Rare occurrence of amplification of HER-2 (erbB-2/neu) oncogene in ovarian cancer patients.

Imyanitov EN, Chernitsa OI, Serova OM, Knyazev PG.

Eur J Cancer. 1992;28A(6-7):1300. No abstract available.

PMID:
1627405
40.

Amplification of ERBB-2 (HER-2/NEU) oncogene in different neoplasms of patients from USSR.

Knyazev PG, Imyanitov EN, Chernitca OI, Nikiforova IF, Hanson KP.

Oncology. 1992;49(2):162-5.

PMID:
1349430
41.
42.

Restriction fragment length polymorphism of the c-Ha-ras-1 proto-oncogene as a marker of genome alterations and susceptibility to the development of some human carcinomas.

Knyazev PG, Nikiforova IF, Serova OM, Novikov LB, Pluzhnikova GF, Abramov AM, Seitz JF.

Haematol Blood Transfus. 1989;32:433-5. No abstract available.

PMID:
2576239
43.

Molecular-genetic analysis of myc and c-Ha-ras proto-oncogene alterations in human carcinoma.

Knyazev PG, Fedorov SN, Serova OM, Pluzhnikova GF, Novikov LB, Kalinovsky VP, Seitz JF.

Haematol Blood Transfus. 1987;31:469-73. No abstract available.

PMID:
3327782
44.

Virus-specific sequences in nuclear DNA from non-producer hamster Rous sarcoma.

Ratovitski EA, Shaposhnikov JD, Gaber VK, Knyazev PG.

Neoplasma. 1979;26(3):251-60.

PMID:
231211
45.

Culture of human cells obtained with DNA from chick Rous sarcoma.

Knyazev PG, Korobitsyn LP, Zhudina AI, Shmelkova VI, Kuznetsov OK, Dyadkova AM, Seitz IF.

Neoplasma. 1976;23(5):483-94.

PMID:
185534

Supplemental Content

Loading ...
Support Center